Literature DB >> 7059425

Verapamil bioavailability and dosage in liver disease.

B G Woodcock, N Rietbrock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7059425      PMCID： PMC1401981          DOI： 10.1111/j.1365-2125.1982.tb01367.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Verapamil and norverapamil plasma concentrations during long-term therapy in patients with hypertrophic obstructive cardiomyopathy.

Authors:  B G Woodcock; R Hopf; M Kaltenbach
Journal:  J Cardiovasc Pharmacol       Date:  1980 Jan-Feb       Impact factor: 3.105

3.  Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.

Authors:  A Somogyi; M Albrecht; G Kliems; K Schäfer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

4.  Physiological disposition of verapamil in man.

Authors:  M Schomerus; B Spiegelhalder; B Stieren; M Eichelbaum
Journal:  Cardiovasc Res       Date:  1976-09       Impact factor: 10.787

5.  Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships.

Authors:  B G Woodcock; I Rietbrock; H F Vöhringer; N Rietbrock
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875
  5 in total
  1 in total

Review 1.  Management of calcium channel antagonist overdose.

Authors:  Steven D Salhanick; Michael W Shannon
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.